$13.89
-0.69-4.73%
At Close: -
$13.89
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Mineralys Therapeutics
MLYSNASDAQ
Mineralys Therapeutics (NASDAQ:MLYS) Stock, Analyst Ratings, Price Targets, Forecasts
Mineralys Therapeutics Inc has a consensus price target of $34.29 based on the ratings of 8 analysts. The high is $45 issued by Stifel on March 7, 2023. The low is $27 issued by Wells Fargo on March 7, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Goldman Sachs, and Credit Suisse on July 10, 2024, April 2, 2024, and August 8, 2023, respectively. With an average price target of $32.33 between HC Wainwright & Co., Goldman Sachs, and Credit Suisse, there's an implied 132.78% upside for Mineralys Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Goldman Sachs
Credit Suisse
Wells Fargo
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Mineralys Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/10/2024 | Buy Now | 115.98% | HC Wainwright & Co. | Matthew Caufield | → $30 | Initiates | → Buy | Get Alert |
| 04/02/2024 | Buy Now | 115.98% | Goldman Sachs | Richard Law | → $30 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | 166.38% | Credit Suisse | Richard Law | $38 → $37 | Maintains | Outperform | Get Alert |
| 05/16/2023 | Buy Now | 173.58% | Credit Suisse | Richard Law | → $38 | Reiterates | Outperform → Outperform | Get Alert |
| 03/16/2023 | Buy Now | 173.58% | Credit Suisse | Richard Law | $40 → $38 | Maintains | Outperform | Get Alert |
| 03/07/2023 | Buy Now | — | Evercore ISI Group | Umer Raffat | — | Initiates | → Outperform | Get Alert |
| 03/07/2023 | Buy Now | 94.38% | Wells Fargo | Mohit Bansal | → $27 | Initiates | → Overweight | Get Alert |
| 03/07/2023 | Buy Now | 187.98% | Credit Suisse | Richard Law | → $40 | Initiates | → Outperform | Get Alert |
| 03/07/2023 | Buy Now | 130.38% | Guggenheim | Seamus Fernandez | → $32 | Initiates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 180.78% | B of A Securities | Greg Harrison | → $39 | Initiates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 223.97% | Stifel | Annabel Samimy | → $45 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Mineralys Therapeutics (MLYS) stock?
The latest price target for Mineralys Therapeutics (NASDAQ:MLYS) was reported by HC Wainwright & Co. on July 10, 2024. The analyst firm set a price target for $30.00 expecting MLYS to rise to within 12 months (a possible 115.98% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Mineralys Therapeutics (MLYS)?
The latest analyst rating for Mineralys Therapeutics (NASDAQ:MLYS) was provided by HC Wainwright & Co., and Mineralys Therapeutics initiated their buy rating.
When was the last upgrade for Mineralys Therapeutics (MLYS)?
There is no last upgrade for Mineralys Therapeutics
When was the last downgrade for Mineralys Therapeutics (MLYS)?
There is no last downgrade for Mineralys Therapeutics.
When is the next analyst rating going to be posted or updated for Mineralys Therapeutics (MLYS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mineralys Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mineralys Therapeutics was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
Is the Analyst Rating Mineralys Therapeutics (MLYS) correct?
While ratings are subjective and will change, the latest Mineralys Therapeutics (MLYS) rating was a initiated with a price target of $0.00 to $30.00. The current price Mineralys Therapeutics (MLYS) is trading at is $13.89, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.